Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Editorial

Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Staab-Weijnitz CA, Eickelberg O

Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition

Thorax 2016;71:675-676.